|
|
News Breaks
|
February 8, 2012
|
| 09:12 EDT |  | AVNR |
| theflyonthewall.com: | Avanir Pharmaceuticals' AVP-923 for diabetis shows positive Phase III results | | Avanir Pharmaceuticals announced the results of the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study". "AVP-923 was proven to be effective, with an acceptable safety profile, for treatment of diabetic peripheral neuropathic pain. The findings indicate that other fixed-dose combinations of AVP-923 should be studied to improve overall tolerability while maintaining significant efficacy," said Aziz Shabaini, MD, Medical Director of the Nerve and Muscle Center, Texas. :theflyonthewall.com |
|
|
News For AVNR From The Last 14 Days Check below for free stories on AVNR the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
